List of Excipients in Branded Drug SIGNIFOR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	SIGNIFOR	pasireotide	0078-0633	MANNITOL	2026-12-14
Novartis Pharmaceuticals Corporation	SIGNIFOR	pasireotide	0078-0633	SODIUM HYDROXIDE	2026-12-14
Novartis Pharmaceuticals Corporation	SIGNIFOR	pasireotide	0078-0633	TARTARIC ACID	2026-12-14
Novartis Pharmaceuticals Corporation	SIGNIFOR	pasireotide	0078-0633	WATER	2026-12-14
Recordati Rare Diseases Inc	SIGNIFOR	pasireotide	55292-131	MANNITOL	2026-12-14

Signifor Excipient Strategy, Formulation Patents and Commercial Opportunities

Last updated: August 23, 2026

Signifor is Novartis' pasireotide product franchise for Cushing's disease and acromegaly. Its commercial protection depends on two distinct formulations: the immediate-release subcutaneous injection, Signifor, and the long-acting intramuscular depot, Signifor LAR. The main excipient opportunity is not a simple substitution of mannitol or buffering agents. It is the development of a bioequivalent, stable injectable or depot system that reproduces pasireotide exposure, injection performance, storage conditions, and device compatibility.

The most defensible commercial targets are:

1. Generic or branded-generic pasireotide injection.
2. A pasireotide pamoate microsphere depot.
3. Excipient and process supply for PLGA-based long-acting injectables.
4. Reformulated presentations that reduce reconstitution burden or injection volume.
5. Regional licensing of manufacturing technology and regulatory dossiers.

What is Signifor and which formulations are commercially relevant?

Signifor contains pasireotide, a cyclohexapeptide somatostatin analog with activity at multiple somatostatin receptor subtypes, including a high affinity for somatostatin receptor 5. It is marketed in two dosage forms.

Product	Active ingredient	Route	Main use	Formulation type
Signifor injection	Pasireotide di-aspartate	Subcutaneous	Cushing's disease; acromegaly in applicable markets	Aqueous immediate-release solution
Signifor LAR	Pasireotide pamoate	Intramuscular	Acromegaly and Cushing's disease, subject to jurisdiction	PLGA-based depot microsphere suspension

The immediate-release product is supplied in single-dose ampoules or vials depending on market. Signifor LAR is supplied as a powder and solvent kit that requires reconstitution before deep intramuscular administration. The LAR product creates a more substantial formulation and manufacturing barrier because its performance depends on polymer characteristics, microsphere structure, particle-size distribution, drug loading, release kinetics, and reconstitution behavior. [1,2]

What excipients are used in Signifor injection?

The immediate-release formulation uses a relatively simple aqueous excipient system. Public product information identifies mannitol and tartaric acid, with sodium hydroxide used for pH adjustment and water for injection as the vehicle. The pasireotide salt is pasireotide di-aspartate. [1]

Component	Function
Pasireotide di-aspartate	Active pharmaceutical ingredient and salt form
Mannitol	Tonicity adjustment and bulking agent
Tartaric acid	Acidic buffering and pH control
Sodium hydroxide	pH adjustment
Water for injection	Injectable vehicle

This composition creates limited differentiation opportunities for conventional excipient suppliers. Mannitol, tartaric acid and sodium hydroxide are widely available commodities. The higher-value opportunity is an equivalent product with demonstrated control of peptide stability, particulate matter, pH, osmolality and container-closure compatibility.

What are the main formulation risks for a Signifor injection competitor?

The formulation is simple but not risk-free. Pasireotide is a peptide, so the principal development issues include:

• Adsorption to glass, elastomeric closures or manufacturing surfaces.
• Aggregation or degradation during storage.
• pH-dependent solubility and stability.
• Particulate formation after extended storage.
• Extractables and leachables from the primary container.
• Dose accuracy in a low-volume subcutaneous presentation.
• Comparability of salt form, concentration and pH.

A competitor could pursue a ready-to-use prefilled syringe, cartridge or autoinjector. That strategy would create a device and container-closure differentiation point but would also increase combination-product and human-factors requirements.

What excipients are used in Signifor LAR?

Signifor LAR uses pasireotide pamoate in a biodegradable polymer depot. The powder contains a PLGA polymer system and stabilizing or processing excipients. The reconstitution solvent contains excipients that control wetting, suspension behavior and injection performance. Public labeling identifies PLGA, mannitol, carboxymethylcellulose sodium and poloxamer 188 in the product system, with the solvent containing mannitol, carboxymethylcellulose sodium and polysorbate 80, together with water for injection. Exact quantities and component allocation should be read from the applicable market-specific label. [2,3]

Excipient or material	Likely technical role
Poly(D,L-lactide-co-glycolide), or PLGA	Biodegradable microsphere matrix and release-control polymer
Mannitol	Bulking agent, tonicity modifier and lyophilized-cake support
Carboxymethylcellulose sodium	Suspending and viscosity-control agent
Poloxamer 188	Wetting and interfacial stabilization
Polysorbate 80	Surfactant in the reconstitution vehicle
Water for injection	Solvent vehicle

The LAR formulation is the more attractive commercial target because the excipient system is inseparable from the manufacturing process. A nominally similar PLGA composition may produce different release profiles because of polymer molecular weight, lactide:glycolide ratio, end-group chemistry, porosity, residual solvent and microsphere size.

What excipient strategy best supports a Signifor generic?

The immediate-release and LAR products require different strategies.

Immediate-release pasireotide strategy

A generic injection should prioritize regulatory similarity over novel excipient differentiation. The preferred approach is:

1. Use the same active salt form where feasible.
2. Match concentration, pH and osmolality.
3. Use compendial-grade mannitol and tartaric acid.
4. Demonstrate peptide stability in the proposed container.
5. Select a low-adsorption glass or polymer presentation.
6. Avoid unnecessary preservative changes in a single-dose product.

A novel excipient may create additional toxicology and regulatory requirements without providing a commercial advantage. The strongest opportunity is cost reduction through reliable sourcing, fill-finish efficiency and a simpler presentation.

LAR depot strategy

A depot competitor should treat the polymer and process as the core intellectual property. Key development variables include:

• PLGA lactide:glycolide ratio.
• Polymer molecular-weight distribution.
• Polymer end-group chemistry.
• Microsphere diameter and distribution.
• Drug loading and encapsulation efficiency.
• Residual solvent.
• Initial burst release.
• Polymer erosion and late-stage release.
• Reconstitution time.
• Needle gauge and injection force.
• Suspension uniformity during administration.

The most commercially useful formulation improvement would reduce preparation errors. Signifor LAR requires a powder-and-solvent kit and trained administration. A ready-to-use suspension, dual-chamber syringe or simplified reconstitution system could improve clinic workflow, although it would require extensive comparability and device validation.

What formulation patents protect Signifor?

Signifor protection is likely divided among composition-of-matter, therapeutic-use, salt, formulation, depot and manufacturing claims. The relevant patent categories are:

Patent category	Commercial relevance
Pasireotide composition patents	Protect the active compound and selected chemical forms
Salt-form patents	May protect pasireotide di-aspartate or pasireotide pamoate
Injectable formulation patents	May cover concentration, pH, excipient ratios or stability
PLGA depot patents	May cover microsphere composition, loading and release characteristics
Method-of-use patents	May cover treatment of Cushing's disease or acromegaly
Manufacturing patents	May cover encapsulation, drying, solvent removal or particle classification
Device patents	May cover reconstitution, delivery and administration systems

The FDA label does not establish the complete patent estate. Orange Book patent listings, patent-family records and litigation dockets must be read separately. For an injectable product, process and formulation patents can remain commercially important even when the principal active-ingredient patents have expired. Orange Book-listed patents are relevant to an abbreviated new drug application, while non-listed formulation, manufacturing and device patents may still support litigation or licensing claims. [4,5]

When does Signifor lose exclusivity?

FDA approval dates provide the regulatory timeline, but they do not alone establish the final generic-entry date.

Milestone	Signifor franchise
Signifor injection approval	FDA approval in 2012 for Cushing's disease
Signifor LAR approval	FDA approval in 2014 for acromegaly
Cushing's disease LAR expansion	Approved in a later supplemental indication
Regulatory exclusivity	Depends on the applicable indication, formulation and approval pathway
Patent exclusivity	Depends on issued patents, patent-term adjustment, pediatric extension and any litigation settlement

The 2012 and 2014 approval dates indicate that ordinary five-year new-chemical-entity exclusivity would have expired years ago. Any remaining U.S. exclusivity is therefore more likely to derive from patents, indication-specific protection, pediatric exclusivity, or settlement terms rather than basic NCE exclusivity. [4]

What is the Orange Book status of Signifor?

Signifor and Signifor LAR are prescription injectable products approved under separate applications or formulation presentations. Orange Book analysis should distinguish:

• The immediate-release pasireotide injection.
• The pasireotide pamoate LAR formulation.
• Patents listed against each application.
• Patent expiration dates and pediatric extensions.
• Whether listed patents claim the drug substance, formulation, method of use or device.

A Paragraph IV applicant would need to address each relevant listed patent. A certification that a patent is invalid, unenforceable or not infringed can create litigation exposure within the statutory notice period. The absence of a listed formulation patent would not eliminate risk from manufacturing, trade-secret or non-listed patent claims. [4,6]

Which companies are challenging Signifor?

Publicly visible competition is more limited than in high-volume peptide markets. Pasireotide competes clinically with other somatostatin analogs and endocrine therapies, but direct generic competition depends on an ANDA or equivalent regulatory filing.

The main competitive groups are:

Competitor group	Products or strategy	Threat level
Generic injectable manufacturers	Pasireotide immediate-release injection	Moderate, subject to patents and technical equivalence
Long-acting injectable specialists	PLGA microsphere or depot pasireotide	High technical barrier
Somatostatin analog companies	Octreotide and lanreotide products	High therapeutic substitution risk
Endocrine drug companies	Medical therapies for Cushing's disease or acromegaly	Moderate to high
Contract development and manufacturing organizations	PLGA microsphere platforms	Enabling rather than direct competition

A generic Signifor injection is a more accessible opportunity than a generic Signifor LAR. LAR competition requires specialized aseptic microsphere manufacturing and a robust clinical and in vitro release package.

What generic launch risks exist for Signifor?

Immediate-release launch scenario

The most plausible first-entry scenario is a pasireotide injection that matches the reference product's concentration, salt, route and presentation. Pricing pressure would likely be greater than for LAR because the formulation uses common excipients and does not require complex depot manufacturing.

Commercial constraints include the small patient population, specialty distribution and the need for endocrinology-focused market access. A single generic entrant may have limited incentive to invest in multiple presentations.

LAR launch scenario

A Signifor LAR competitor faces greater risks:

• Failure to match pharmacokinetic exposure.
• Inadequate control of initial burst release.
• Reconstitution failures.
• High injection force or needle blockage.
• Inconsistent microsphere loading.
• Residual solvent or polymer impurity findings.
• Scale-up changes affecting release performance.
• Need for clinical bridging or extensive comparative data.

The LAR opportunity is commercially attractive only if the developer can achieve a material cost, convenience or supply advantage. A technically equivalent product with no price or administration benefit may not justify the development cost.

How strong is the Signifor patent estate?

The estate is strongest around the long-acting delivery system and weakest around the commodity excipients used in the immediate-release injection. A practical risk ranking is:

Asset	Patent and technical defensibility
Mannitol-tartaric acid aqueous injection	Low to moderate
Pasireotide di-aspartate injectable presentation	Moderate, depending on active patent coverage
Pasireotide pamoate salt	Moderate to high if valid claims remain
PLGA pasireotide microspheres	High technical barrier; patent strength depends on claim scope
Reconstitution kit and delivery device	Moderate
Manufacturing process	Moderate to high where trade secrets and narrow process claims apply
Treatment methods	Variable, often vulnerable to indication-specific certifications

The most durable barrier may be manufacturing know-how rather than a single broad excipient claim. Microsphere particle engineering, scale-up parameters and release testing can be difficult to replicate from public documents.

What licensing deals and supply opportunities exist?

The most realistic licensing opportunities are platform-based rather than molecule-only. Potential transactions include:

• Regional rights to a pasireotide injection dossier.
• Licensing of a PLGA microsphere manufacturing process.
• Contract manufacture of pasireotide pamoate microspheres.
• Dual sourcing of pharmaceutical-grade PLGA.
• Supply of low-endotoxin mannitol, carboxymethylcellulose sodium or surfactants.
• Co-development of a prefilled or dual-chamber presentation.
• Technology transfer for aseptic lyophilization and reconstitution systems.

Excipient suppliers should avoid treating Signifor as a high-volume opportunity. The value lies in qualification, regulatory documentation, batch consistency and integration into a drug-product platform that can support other long-acting peptides.

How does Signifor compare with competing somatostatin analogs?

Product	Active ingredient	Delivery	Excipient opportunity
Signifor	Pasireotide	Subcutaneous solution	Low-complexity aqueous injectable
Signifor LAR	Pasireotide pamoate	Monthly intramuscular depot	High-complexity PLGA microsphere
Sandostatin LAR	Octreotide acetate	Intramuscular depot	Established microsphere competition
Somatuline Depot	Lanreotide acetate	Deep subcutaneous depot	Different peptide and gel/depot platform

Signifor LAR's competitive value is linked to receptor pharmacology and clinical positioning, but its formulation economics are less favorable than conventional solutions. A supplier that can transfer microsphere process expertise from octreotide or other peptide depots may have a meaningful development advantage, subject to freedom-to-operate constraints.

What is the revenue exposure and commercial opportunity?

Signifor addresses rare endocrine disorders, so total volume is limited. The commercial model depends on high specialty-drug pricing, chronic treatment and restricted competition. Revenue exposure is concentrated in:

• Reimbursement for Cushing's disease and acromegaly.
• Continued use of the monthly LAR formulation.
• Prescriber acceptance of pasireotide despite hyperglycemia risk.
• Availability of specialty pharmacy and clinic administration.
• Generic timing and any authorized-generic strategy.

The immediate-release product offers a lower-cost entry point for a generic manufacturer. The LAR formulation offers more defensible margins but requires substantially higher development and manufacturing investment. For excipient companies, the best opportunity is to sell enabling technology across several depot products rather than rely on Signifor demand alone.

Key Takeaways

• Signifor has two distinct formulation opportunities: an aqueous pasireotide injection and a PLGA-based pasireotide pamoate depot.
• Mannitol and tartaric acid are unlikely to provide meaningful standalone differentiation in the immediate-release product.
• The principal LAR barrier is microsphere process control, not the identity of any single excipient.
• PLGA grade, polymer molecular weight, particle size, drug loading and release profile are central commercial and regulatory variables.
• A generic Signifor injection is more accessible than a generic Signifor LAR.
• A ready-to-use or simplified reconstitution presentation could create commercial differentiation.
• Orange Book analysis must be separated from non-listed formulation, manufacturing, device and trade-secret risks.
• The most valuable licensing assets are likely depot manufacturing platforms, regulatory dossiers and qualified excipient supply chains.

FAQs About Signifor Excipient and Formulation Opportunities

Is Signifor a biologic or a small-molecule drug?

Signifor contains pasireotide, a synthetic peptide drug. It is regulated as a drug rather than as a biologic under the FDA approval framework described in its product labeling. [1]

Does Signifor LAR use PLGA?

Yes. Signifor LAR uses a biodegradable PLGA microsphere system to provide prolonged intramuscular release of pasireotide pamoate. [2]

Can a generic company replace the Signifor excipients?

An ANDA applicant generally must demonstrate pharmaceutical equivalence and bioequivalence. Excipient changes may be possible, but they can affect stability, injection performance, release kinetics and regulatory comparability.

Is biosimilar competition relevant to Signifor?

No. Signifor is not a biologic reference product for a biosimilar pathway. Competition would arise through generic-drug, hybrid, or jurisdiction-specific equivalent-product pathways.

Which Signifor presentation has the greater commercial barrier?

Signifor LAR has the greater barrier because it combines a peptide salt, biodegradable microspheres, controlled release, aseptic manufacturing and a reconstitution-and-injection system.

References

1. U.S. Food and Drug Administration. (2023). Signifor (pasireotide diaspartate) injection: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Signifor LAR (pasireotide pamoate) for injectable suspension: Prescribing information. FDA.

3. Novartis Pharmaceuticals Corporation. (2023). Signifor and Signifor LAR product information. Novartis.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. European Medicines Agency. (2024). Signifor: European public assessment report and product information. EMA.

6. U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and patent certifications. FDA.